Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets
Poster Jan 19, 2017
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.
Current methods used to measure the activity of antibody and other biologics drugs designed to target immune checkpoint receptors rely on primary human cells and measurement of functional endpoints such as cell proliferation, cell surface marker expression, and cytokine production. These assays are laborious and highly variable due to their reliance on donor primary cells, complex assay protocols, and unqualified assay reagents. As a result, these assays are difficult to establish in quality-controlled drug development settings.
To overcome these challenges, we developed a suite of cell-based bioluminescent reporter bioassays for individual and combination immune checkpoint immunotherapy targets including:
• PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT
• GITR, 4-1BB, CD40, OX40
These mechanism of action (MOA)-based bioassays are available in “thaw-and-use” format and demonstrate high specificity, sensitivity, and reproducibility. The bioassays are qualified according to ICH guidelines and demonstrate the performance required for use in antibody screening, potency testing, and stability studies.
Is Oxford Nanopore Technology Ready for Clinical Diagnostics?Poster
Our objective is to validate diagnostic services using Oxford Nanopore’s Minion in the first instance and to evaluate the cost and performance compared to existing sequencing technology in areas such as tumour DNA sequencing (and circulating tumour DNA), virology, microbiology, genetics and HLA-typing.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE